Quoin Pharmaceuticals Ltd. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Quoin Pharmaceuticals Ltd. (QNRX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$1.79 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2025-11-06
- Quoin Pharmaceuticals Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $198.78K.
- Quoin Pharmaceuticals Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$567.67K, a 211.04% decline year-over-year.
- Quoin Pharmaceuticals Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $511.23K.
- Quoin Pharmaceuticals Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$2.29M.
- Quoin Pharmaceuticals Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $1.22M.
- Quoin Pharmaceuticals Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$459.43K.
- Quoin Pharmaceuticals Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$4.62M, a 164.56% decline from fiscal 2021.
- Quoin Pharmaceuticals Ltd. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $7.16M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$1.79M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$1.95M 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $198.78K 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $1.22M 10-K · filed 2025-03-13 | |||
| 2024-09-30 | $715.55K 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $443.93K 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$567.67K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$459.43K 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $302.80K 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | $1.90M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $511.23K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$4.62M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | -$2.23M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | -$4.79M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$2.29M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $7.16M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $328.96K 6-K · filed 2022-11-10 | |||
| 2021-06-30 | $1.40M 6-K · filed 2022-08-18 | |||
| 2020-12-31 | $323.83K 20-F · filed 2022-04-14 | |||
| 2019-12-31 | -$40.00 20-F · filed 2022-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |